Market Spotlight: Dry Eye Disease
Market Spotlight: Dry Eye Disease
$1,318.00
This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 1.54 billion prevalent cases of dry eye disease worldwide, and forecasts that number to increase to 1.75 billion prevalent cases by 2030.
- The approved drugs in the dry eye space focus on a wide variety of targets. The majority of approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival and intranasal formulations.
- The majority of industry-sponsored drugs in active clinical development for dry eye are in Phase II, with two products in the NDA/BLA stage.
- Therapies in development for dry eye focus on a wide variety of targets. The majority of pipeline drugs are administered via the topical route.
- High-impact upcoming events for drugs in the dry eye space comprise topline Phase II, Phase II/III, and Phase III trial results, as well as expected PDUFA dates.
- The overall likelihood of approval of a Phase I dry eye asset is 13.8%, and the average probability a drug advances from Phase III is 36.8%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 8.8 years in the overall ophthalmology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for dry eye have been in the late phases of development, with 57% of trials in Phase III–IV compared to 43% in Phase I–II.
- The US has a substantial lead in the number of dry eye clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the dry eye space is dominated by completed trials. Novartis has the highest number of completed clinical trials for dry eye, with 82 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for dry eye, followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
10 TREATMENT
10 Ocular lubricants
10 Prescription drugs
11 Eyelid hygiene
12 Surgical treatment
13 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 OCS-02 for Dry Eye (July 6, 2022)
28 Reproxalap for Dry Eye (June 8, 2022)
30 ST-100 for Dry Eye (January 3, 2022)
31 CyclASol for Dry Eye (December 21, 2021)
33 OTX-DED for Dry Eye (December 6, 2021)
34 OTX-CSI for Dry Eye (October 22, 2021)
36 NovaTears for Dry Eye (September 30, 2021)
37 AR-15512 for Dry Eye (September 15, 2021)
39 NovaTears for Dry Eye (April 13, 2021)
42 KEY UPCOMING EVENTS
43 KEY REGULATORY EVENTS
43 Novaliq Platform Supports Two Dry Eye NDAs
43 Théa Invests Further In UK With Latest Dry Eye Launch
43 Thea Pharmaceuticals Adds Reusable Eye Compress To UK Blepha Range
44 Viatris Readies Restasis Launch – So Where Are The Others?
44 Oyster Point Prepares Major Push For New Dry Eye Drug
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
46 Alcon Buys Aerie, Reaffirming Commitment To Pharma Space
46 Alcon Pays $60m Up Front For Two Kala Eye Care Therapies
46 Acquisition By HLB Group To Speed Up GtreeBNT’s Programs
48 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
55 BIBLIOGRAPHY
56 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in prevalent cases of dry eye disease, 2021–30
20 Figure 2: Overview of pipeline drugs for dry eye disease in the US
20 Figure 3: Pipeline drugs for dry eye disease, by company
21 Figure 4: Pipeline drugs for dry eye disease, by drug type
21 Figure 5: Pipeline drugs for dry eye disease, by classification
28 Figure 6: OCS-02 for Dry Eye (July 6, 2022): Phase II – 2202
30 Figure 7: Reproxalap for Dry Eye (June 8, 2022): Phase III – TRANQUILITY 2
33 Figure 8: CyclASol for Dry Eye (December 21, 2021): Phase III – ESSENCE-2
34 Figure 9: OTX-DED for Dry Eye (December 6, 2021): Phase II – OTX-DED-2020-201
36 Figure 10: OTX-CSI for Dry Eye (October 22, 2021): Phase II – w/Vehicle
37 Figure 11: NovaTears for Dry Eye (September 30, 2021): Phase III – MOJAVE
39 Figure 12: AR-15512 for Dry Eye (September 15, 2021): Phase IIb – COMET-1
41 Figure 13: NovaTears for Dry Eye (April 13, 2021): Phase III – GOBI
42 Figure 14: Key upcoming events in dry eye disease
45 Figure 15: Probability of success in the dry eye pipeline
49 Figure 16: Clinical trials in dry eye disease
49 Figure 17: Top 10 drugs for clinical trials in dry eye disease
50 Figure 18: Top 10 companies for clinical trials in dry eye disease
50 Figure 19: Trial locations in dry eye disease
51 Figure 20: Dry eye disease trials status
52 Figure 21: Dry eye disease trials sponsors, by phase
LIST OF TABLES
14 Table 1: Prevalent cases of dry eye disease, 2021–30
18 Table 2: Marketed drugs for dry eye disease
22 Table 3: Pipeline drugs for dry eye disease in the US
27 Table 4: OCS-02 for Dry Eye (July 6, 2022)
29 Table 5: Reproxalap for Dry Eye (June 8, 2022)
31 Table 6: ST-100 for Dry Eye (January 3, 2022)
32 Table 7: CyclASol for Dry Eye (December 21, 2021)
33 Table 8: OTX-DED for Dry Eye (December 6, 2021)
35 Table 9: OTX-CSI for Dry Eye (October 22, 2021)
36 Table 10: NovaTears for Dry Eye (September 30, 2021)
38 Table 11: AR-15512 for Dry Eye (September 15, 2021)
40 Table 12: NovaTears for Dry Eye (April 13, 2021)
48 Table 13: Historical global sales, by drug ($m), 2017–21
48 Table 14: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Systemic Lupus Erythematosus (SLE) 
Sign up to the